跳至主要内容
临床试验/NCT04576741
NCT04576741已完成不适用

Testing the Feasibility and Acceptability of a Blended Mindfulness-Based Intervention for Persistent Depression

University of Surrey1 个研究点 分布在 1 个国家目标入组 24 人开始时间: 2021年3月1日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
24
试验地点
1
主要终点
Reductions in depression symptomatology as assessed using the Patient Health Questionnaire-9 (PHQ-9), change measured within 1 week of starting and finishing the course and in week 5 and 9.

研究概览

简要总结

We plan to share all IPD but not any personal information.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者
否

入选标准

  • •A current diagnosis of Major Depression as assessed by Structured Clinical Interview for DSM IV (First, Spitzer, Gibbon, & Williams, 2002).
  • •A chronic or recurrent lifetime history of depression, with either chronic persistence of symptoms or a history of at least three previous episodes of depression, two of which needed to have occurred during the last two years.
  • •Self-reported severity of current symptoms on a clinical level as indicated by a PHQ-9 score of 10 or more.
  • •Age 18 to 65 thus excluding cases of late life depression given that such cases might differ in aetiology.
  • •Fluency in spoken and written English.
  • •Have individual access to a computer or mobile device with internet connection and video link.

排除标准

  • •History of schizophrenia, schizoaffective disorder, bipolar disorder, current abuse of alcohol or other substances, organic mental disorder, pervasive developmental delay, primary diagnosis of obsessive-compulsive disorder or eating disorder, or regular nonsuicidal self-injury.
  • •Current treatment with CBT more than once a month.
  • •Regular meditation practice (meditating more than once per week).
  • •Inability to complete research assessments through difficulty with English, visual impairment, or cognitive difficulties.
  • •We will allow patients who are currently taking antidepressants into the study provided that the medication has not been changed during the last four weeks before entry into the study.

研究组 & 干预措施

bMBI standard practice

Experimental

This is a 12-week online mindfulness-based course blended with therapist support via video link using standard practices for Mindfulness-Based Cognitive Therapy (30-minutes/day).

干预措施: bMBI standard practice (Behavioral)

bMBI shorter more frequent practice

Experimental

This is a 12-week online mindfulness-based course blended with therapist support via video link using shorter, more frequent practice than standard Mindfulness-Based Cognitive Therapy (2x15-minutes/day).

干预措施: bMBI shorter more frequent practice (Behavioral)

结局指标

主要结局

Reductions in depression symptomatology as assessed using the Patient Health Questionnaire-9 (PHQ-9), change measured within 1 week of starting and finishing the course and in week 5 and 9.

时间窗: Weeks 0, 5, 9,13.

The PHQ-9 has 9 questions to assess the presence and severity of depression according to DSM-IV criteria and takes less than 3 minutes to complete. The PHQ-9 asks about patients' experiences in the last 2 weeks in relation to depression. Responses range from "0" (not at all) to "3" (nearly every day). Presence and severity of depression is scored as follows: 0-4 = minimal, 5-9 = mild, 10-14 = moderate, 15-19 moderately severe, 20-27 = severe. The PHQ-9 has been found to have a high level of validity and reliability (Kroenke, Spitzer, \& Williams, 2001).

次要结局

  • Levels of mindfulness in daily life as assessed using the Five-Facet Mindfulness Questionnaire (FFMQ-15), change measured within 1 week of starting and finishing the course and in week 5 and 9.(Weeks 0, 5, 9,13.)
  • Symptoms of anxiety as assessed using the Generalised Anxiety Disorder Assessment (GAD-7), change measured within 1 week of starting and finishing the course and in week 5 and 9.(Weeks 0, 5, 9,13.)
  • Ability to decenter as assessed by self-report on the Experiences Questionnaire (EQ), change measured within 1 week of starting and finishing the course and in week 5 and 9.(Weeks 0, 5, 9,13.)
  • Mind wandering and spontaneous thoughts as assessed by the Amsterdam Resting-State Questionnaire 2.0 (ARSQ 2.0), change measured within 1 week of starting and finishing the course and in week 5 and 9.(Weeks 0, 5, 9,13.)
  • Subjective levels of stress as assessed using the Perceived Stress Scale (PSS), change measured within 1 week of starting and finishing the course and in week 5 and 9.(Weeks 0, 5, 9,13.)
  • Mental wellbeing as assessed using the Warwick-Edinburgh Mental Wellbeing Scale (WEMWBS), change measured within 1 week of starting and finishing the course and in week 5 and 9.(Weeks 0, 5, 9,13.)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验

招募中
不适用
Pilot to examine the feasibility of collecting biomarkers in the Longitudinal Internet panel study for the Social Sciences (LISS)de studie focust op risico factoren, namelijk cholestrol, cortisol en buikomvang, en niet op specifieke ziekten.niet van toepassing
NL-OMON31590Erasmus MC, Universitair Medisch Centrum Rotterdam600
进行中(未招募)
1 期
Seguridad, tolerabilidad y eficacia a largo plazo de AFQ056 en pacientes adultos con síndrome X frágilFragile X SyndromeMedDRA version: 14.1Level: PTClassification code 10017324Term: Fragile X syndromeSystem Organ Class: 10010331 - Congenital, familial and genetic disorders
EUCTR2011-001952-12-ESovartis Farmacéutica S.A148
招募中
不适用
Building a platform for surveying and sharing information on patients with inflammatory bowel disease using social network services.Inflammatory bowel disease, Crohn's disease, ulcerative colitis
JPRN-UMIN000047474Tohoku University Hospital500
招募中
不适用
Collection of Blood for Multiple Collaborative StudiesHIV
NCT01336855University of California, San Francisco2,000
进行中(未招募)
不适用
Open study to assess the tolerability, safety and efficacy of an adapted 2 litre gut cleansing solution (NRL0706) in routine colon cleansing prior to colonoscopies for colon tumour screeningMedDRA version: 12.0Level: LLTClassification code 10010007Term: ColonoscopySubjects without relevant clinical symptoms for gastrointestinal disorders will undergo a complete selective colonoscopy for colon cancer screening.
EUCTR2009-014845-95-DEorgine Ltd.